Lineage Cell Therapeutics (LCTX) Cost of Revenue (2011 - 2025)
Lineage Cell Therapeutics (LCTX) posted quarterly Cost of Revenue of $66000.0 for Q4 2025, down 57.14% year-over-year from $154000.0 in Q4 2024, and up 1220.0% quarter-over-quarter from $5000.0 in Q3 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Cost of Revenue (2011 - 2025) Analysis & Trends
Lineage Cell Therapeutics' Cost of Revenue history runs 15 years deep, the most recent figure standing at $66000.0 for Q4 2025.
- In Q4 2025, Cost of Revenue fell 57.14% year-over-year to $66000.0; the TTM figure through Mar 2026 stood at $110000.0 (down 59.56% YoY), while the FY2025 annual figure was $146000.0, down 56.29% from the prior year.
- Cost of Revenue for Q4 2025 stood at $66000.0, up from $5000.0 in the prior quarter.
- The five-year high for Cost of Revenue was $985000.0 in Q3 2021, with the low at $5000.0 in Q3 2025.
- The 5-year median for Cost of Revenue is $122000.0 (2021), against an average of $165250.0.
- The sharpest annual moves came in 2021 and 2025: Cost of Revenue jumped 865.69% in 2021, then tumbled 86.84% in 2025.
- Lineage Cell Therapeutics' Cost of Revenue stood at $204000.0 in 2021, then slumped by 50.0% to $102000.0 in 2022, then jumped by 150.98% to $256000.0 in 2023, then slumped by 39.84% to $154000.0 in 2024, then sank by 57.14% to $66000.0 in 2025.
- Business Quant data shows LCTX's Cost of Revenue at $66000.0 in Q4 2025, $5000.0 in Q3 2025, and $39000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 66,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Dec 31, 2024 | 154,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Dec 31, 2023 | 256,000.00 |
| Sep 30, 2023 | 169,000.00 |
| Jun 30, 2023 | 127,000.00 |
| Mar 31, 2023 | 119,000.00 |
| Dec 31, 2022 | 102,000.00 |
| Sep 30, 2022 | 235,000.00 |
| Jun 30, 2022 | 215,000.00 |
| Mar 31, 2022 | 176,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Sep 30, 2021 | 985,000.00 |
| Jun 30, 2021 | 125,000.00 |
| Mar 31, 2021 | 112,000.00 |